Biotechnology
Company Overview of Affectis Pharmaceuticals AG
Company Overview
Affectis Pharmaceuticals AG, a biopharmaceutical company, engages in the development of drugs for the treatment of psychiatric and inflammatory disorders. The company’s products encompass Cimicoxib, which is for the treatment of depression and schizophrenia; AFC-5128, a P2X7 antagonist for the treatment of inflammatory diseases, such as rheumatoid arthritis; P2X7, a novel therapeutic for depression; and AF-08, which is for the treatment of depression. Affectis Pharmaceuticals AG was formerly known as Neuronova AG and changed its name in January 2005. The company was founded in 2004 and is based in Martinsried, Germany.
Fraunhoferstrasse 13
Martinsried, 82152
Germany
Founded in 2004
Key Executives for Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG Key Developments
Affectis Pharmaceuticals AG Presents at 17th Annual BIO Europe 2011, Oct-31-2011 . Venue: CCD Congress Center Duesseldorf, Stockumer Kirchstr, 61, Duesseldorf 40474, North Rhine-Westphalia, Germany.
Affectis Pharmaceuticals AG Presents at 4th Annual International Partnering Conference, BioPharm America 2011, Sep-07-2011 . Venue: Westin Boston Waterfront Hotel, 425 Summer Street, Boston, MA 02210, United States.
Merck Serono S.A. has signed an exclusive licensing agreement with Affectis Pharmaceuticals AG for the development and commercialization of oral compounds targeting P2X7 receptors, which are believed to be involved in neuroinflammation observed in some neurodegenerative diseases. Under the terms agreed, Merck will have worldwide exclusive rights to develop and commercialize selected compounds. The contract also includes a research collaboration focusing on P2X7 antagonist optimization. Affectis will receive EUR 2.4 million in up-front payment and research funding, and could receive up to EUR 277 million in milestones for the first three products to come out of the collaboration, as well as undisclosed royalties.
Similar Private Companies By Industry
| Company Name | Region |
| Almirall Hermal GmbH | Europe |
| Haupt Pharma Wülfing GmbH | Europe |
| Juta Pharma GmbH | Europe |
| Cysal GmbH | Europe |
| Imumed Deutschland Gmbh | Europe |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Citizens Budget Commission | United States |
Post a JobJobs
- Boston, MA | PwCPosted: Aug 28
- Berkeley, CA | BayerPosted: May 17
- Miami, FL | Sterling Life SciencesPosted: May 09
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
Sponsored Links
To contact Affectis Pharmaceuticals AG, please visit www.affectis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
